Innovate UK

Biovit is a company that specializes in the development of fortified foods. It uses 100% organic plant extracts, naturally rich in vitamins and minerals, to enhance the nutritional value of its products. The company aims to address health and environmental issues such as obesity and malnutrition, while also reducing food waste. Biovit has clinically developed and tested organic micronutrient blends for use in various food and beverage products, as well as supplements, providing consumers with organically sourced, nutrient-dense options.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

The Good Pulse is a producer of functional proteins and ingredients derived from pulses, specializing in plant-based foods and supplements. The company focuses on creating meat alternatives and cheese substitutes using precision fermentation techniques. By maximizing the functionality and nutritional value of pulse seeds, such as peas and soy, The Good Pulse aims to provide consumers with sustainable and ethical food options. Their products are designed to ensure that consumers do not have to compromise on taste or experience while adopting a more efficient diet. Through its innovative approach, The Good Pulse is dedicated to revalorizing all components extracted from pulses, contributing to a more sustainable food system.

Calla Lily Clinical Care is a B-Corp focused on women's health, specializing in innovative drug delivery systems. It has developed the proprietary Callavid® platform for intravaginal drug administration, aiming to enhance patient outcomes in fertility and pregnancy. The company is working towards launching the first drug-device combination product designed to prevent miscarriages and provide luteal phase support for In Vitro Fertilization (IVF). Additionally, Callavid® is capable of delivering live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic usage and the spread of antimicrobial resistance. The company also offers the Lilyvid™ device for effective medical sample collection, which facilitates advanced biomarker-based diagnostic tests for conditions such as endometriosis. The technology behind Calla Lily's devices has been recognized as a TIME Magazine Best Invention of the Year, reflecting its innovative approach to women's healthcare.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

BoobyBiome is a company focused on enhancing infant health through the development of probiotic supplements specifically designed for babies with compromised microbiomes. By leveraging specialized expertise and research, BoobyBiome aims to recreate the beneficial bacteria associated with breast milk, particularly for infants born prematurely or those who rely on formula feeding. Their products are formulated to closely mimic the properties of breast milk, providing essential support for gut health and immune system development in infants. Through these innovative probiotic solutions, BoobyBiome seeks to promote healthy growth and development during a critical stage of life.

Calla Lily Clinical Care is a B-Corp focused on women's health, specializing in innovative drug delivery systems. It has developed the proprietary Callavid® platform for intravaginal drug administration, aiming to enhance patient outcomes in fertility and pregnancy. The company is working towards launching the first drug-device combination product designed to prevent miscarriages and provide luteal phase support for In Vitro Fertilization (IVF). Additionally, Callavid® is capable of delivering live biotherapeutics to address recurrent Bacterial Vaginosis, thereby reducing antibiotic usage and the spread of antimicrobial resistance. The company also offers the Lilyvid™ device for effective medical sample collection, which facilitates advanced biomarker-based diagnostic tests for conditions such as endometriosis. The technology behind Calla Lily's devices has been recognized as a TIME Magazine Best Invention of the Year, reflecting its innovative approach to women's healthcare.

Camallergy Limited is a biopharmaceutical company based in Cambridge, United Kingdom, founded in 2015. The company specializes in developing and manufacturing oral immunotherapy drugs, particularly targeting food allergies, with a focus on peanut allergies. Camallergy's lead product offers a novel treatment designed to provide "bite-proof" protection to patients within 14 weeks of therapy. This innovative approach is grounded in unique intellectual property and clinical research initiated at Cambridge University Hospitals NHS Foundation Trust. By aiming to deliver patient-centric solutions, Camallergy seeks to improve the quality of life for individuals suffering from food allergies, allowing them to live without the constant fear of allergic reactions.

Nandi Proteins Limited is a UK-based company, established in 2000 and spun out of Heriot Watt University in 2001. Formerly known as Nandi Biotechnology Limited, the company specializes in developing innovative technologies to enhance the functional properties of proteins used in food manufacturing and nutrition. Nandi Proteins focuses on improving common proteins such as whey, egg, and soy through patented processes that utilize controlled heat, time, and temperature. The company's goal is to lead the market in denatured protein technology, offering value-added protein products and pursuing strategic licensing agreements with industry partners. By leveraging its expertise, Nandi Proteins aims to deliver significant growth and provide manufacturers with the ability to enhance the physical characteristics and health benefits of food and beverage products while also enabling the cost-effective extraction of valuable components.